What Is BODI11's New Offering?
An urgent decision lies ahead for unitholders. BODI11, a Brazilian infrastructure fund managed by Bocaina Capital and administered by BTG Pactual DTVM, approved its second unit offering on October 28, 2026. The fund plans to issue 23.6 million new units to raise an initial R$ 240 million, with an over-allotment option that could push total proceeds to R$ 300 million. Existing unitholders as of the record date hold subscription rights to participate proportionally. For a deeper breakdown of the fund, see our full BODI11 analysis.
The main sticking point is price. The unit closed at R$ 9.65 on the B3 exchange, while the effective subscription price was set R$ 0.52 above that—a 5.4% premium. Participating in the offering costs more than buying units directly in the secondary market today, and unitholders who take no action face significant dilution if the capital raise succeeds.
base price excluding distribution fee, near the R$ 9.87 NAV
total price unitholders pay to exercise rights
closing price on Oct 28; 2% discount to NAV per unit
The breakdown between the offering price and subscription price works as follows:
Why Is the Offering Priced Above Market Value?
Primary offerings create new units rather than trading existing ones. The base offering price of R$ 9.76 was set near the fund's net asset value (NAV) per unit of R$ 9.87—the accounting value of each unit based on mark-to-market valuations of its corporate debenture portfolio. Secondary market trading reflects a 2% discount to NAV (P/NAV of 0.98), but the new issuance does not replicate that market discount.
The primary distribution fee of R$ 0.41 goes entirely to underwriting intermediaries and does not enter the fund's equity. The fund collects only the base offering price for each new unit created, while existing units remain on the balance sheet at NAV. This results in minor NAV dilution for current unitholders, as new capital enters at a base price slightly below current NAV. A similar dynamic played out in HGLG11's 12th offering, which was also priced above market trading levels in August.
How Large Is the Offering—and What Is the Dilution Risk?
The expansion is substantial. The fund currently has R$ 264 million in net assets. The base offering of R$ 240 million almost doubles its current footprint. At maximum deployment (including the R$ 60 million over-allotment), net assets could jump from R$ 264 million to R$ 564 million—2.1 times its current size. In October, ALZR11 also approved a major capital raise that was closely watched by the market.
Unitholders who opt out of the subscription will experience ownership dilution tied directly to the total funds raised. Under maximum subscription, an inactive investor's relative stake in the fund could be reduced by nearly half. Under the minimum subscription threshold—R$ 30 million required for the offering to proceed—dilution is limited to approximately 11%.
The chart reveals only part of the narrative. Monthly distribution per unit rose from R$ 0.10 in March to R$ 0.12–R$ 0.13 between April and September, validating our previous analysis that early yields did not yet reflect a fully deployed portfolio. With this new capital raise, the ramp-up process resets: cash reserves will temporarily sit in floating CDI yields while Bocaina identifies and acquires corporate debentures with target CDI+ spreads.
How Does R$ 240 Million in New Capital Impact the Thesis?
The fund launched in January 2026 tasked with deploying its IPO proceeds. Ten months later, distributions have increased, but NAV per unit has dipped from R$ 10.06 (noted in prior coverage) to R$ 9.87, with secondary market trading anchored at a 2% discount. Now, Bocaina Capital seeks to nearly double the fund's size, requiring management to source additional high-quality debentures without compressing average portfolio yield spreads.
Adverse selection risk—a point highlighted in previous analysis—re-emerges as a central concern. Urgency to allocate a large capital pool can create pressure to compromise on credit quality or yield spreads. While Bocaina's track record with BODB11 (its inflation-linked sibling fund) exhibits no evidence of loose underwriting, the first post-offering management report will serve as the true benchmark. Unitholders should also note that BODI11 holds floating-rate CDI+ assets: if the benchmark Selic rate declines in coming months, newly allocated capital will generate less absolute carry than current levels—unlike inflation-linked funds that lock in fixed yields at acquisition.
What Happens Under Maximum vs. Minimum Capital Raised?
Bocaina deploys R$ 300 million into new CDI+ debentures; the fund gains scale to diversify issuers and lower single-credit risk. Participating unitholders preserve their proportional stake; non-participating unitholders lose nearly half their ownership percentage.
Only the required R$ 30 million minimum threshold is raised to avoid offering cancellation; non-participating unitholders face ~11% dilution. The fund grows modestly, extending the timeline for full portfolio maturation.
In either scenario, unitholders exercising subscription rights pay a price higher than the current market quote. The bullish case rests on the assumption that a mature, fully deployed portfolio of CDI+ debentures will deliver higher yields than the current annualized 6.2% distribution yield. However, that rationale applies equally to buying units cheaper on the open market today rather than subscribing through the offering.
If you hold BODI11, you will receive subscription rights proportional to your position. You face three primary options: (a) exercise your rights to maintain your proportional ownership, though at a cost above secondary market prices; (b) sell your rights on the B3 exchange (if rights trading is enabled) to recover part of the opportunity cost; or (c) take no action, accepting potential ownership dilution if the capital raise succeeds. None of these choices is universally correct—the optimal path depends on your desired portfolio exposure and willingness to pay a premium to preserve relative ownership.
Confirm Key Dates — Check with your brokerage or review B3 filings to confirm the exact rights exercise deadline; the indicative schedule in the Material Fact filing is subject to adjustments.
Check Rights Tradability — If subscription rights are tradable on B3 under a designated ticker, you can sell them to capture residual value without committing new capital.
Compare Market Price Before Exercising — If market prices rise above R$ 10.17 prior to the deadline, secondary trading will have priced the offering favorably; if market prices stay lower, buying open-market units remains more cost-effective.
Monitor Portfolio Spreads Post-Offering — Track average portfolio CDI+ spreads in the first post-offering management report. A contraction in average spreads signals potential adverse selection, while stable or wider spreads confirm disciplined deployment by management.